579 related articles for article (PubMed ID: 27609708)
1. [Fibrates therapy: Rational use fenofibrate 2016. Executive summary].
Brea A; Millán J; Ascaso JF; Blasco M; Díaz A; González-Santos P; Hernández-Mijares A; Mantilla T; Pedro-Botet JC; Pintó X;
Clin Investig Arterioscler; 2016; 28(6):295-301. PubMed ID: 27609708
[TBL] [Abstract][Full Text] [Related]
2. [Consensus for pharmacologic treatment of atherogenic dyslipidemia with statin-fenofibrate combined therapy].
Panel Europeo de Expertos. Versión Española del Grupo de trabajo sobre Dislipemia Aterogénica
Clin Investig Arterioscler; 2016; 28(2):87-93. PubMed ID: 26811267
[TBL] [Abstract][Full Text] [Related]
3. [The fixed combination of pravastatin and fenofibrate: what can it provide?].
Díaz Rodríguez Á
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():12-6. PubMed ID: 25043541
[TBL] [Abstract][Full Text] [Related]
4. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2012 Oct; 11():125. PubMed ID: 23057687
[TBL] [Abstract][Full Text] [Related]
5. [Indications for the combination of pravastatin and fenofibrate according to the type of dyslipidemia].
Núñez-Cortés JM
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():31-4. PubMed ID: 25043545
[TBL] [Abstract][Full Text] [Related]
6. [Indications for the combination of pravastatin and fenofibrate according to the cardiovascular risk level. Common clinical situations].
Pintó X
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():35-9. PubMed ID: 25043546
[TBL] [Abstract][Full Text] [Related]
7. Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.
Moutzouri E; Kei A; Elisaf MS; Milionis HJ
Vasc Health Risk Manag; 2010 Aug; 6():525-39. PubMed ID: 20730069
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy studies].
Pedro-Botet J; Flores-Le Roux JA
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():17-9. PubMed ID: 25043542
[TBL] [Abstract][Full Text] [Related]
9. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
[TBL] [Abstract][Full Text] [Related]
10. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
11. Practical recommendations for the management of cardiovascular risk associated with atherogenic dyslipidemia, with special attention to residual risk. Spanish adaptation of a European Consensus of Experts.
Grupo de trabajo de Dislipemia Aterogénica de la Sociedad Española de Arteriosclerosis y Grupo Europeo de Expertos
Clin Investig Arterioscler; 2017; 29(4):168-177. PubMed ID: 28433209
[TBL] [Abstract][Full Text] [Related]
12. [Combination of pravastatin and fenofibrate (Pravafenix ®). Safety studies].
Hernández Mijares A
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():25-30. PubMed ID: 25043544
[TBL] [Abstract][Full Text] [Related]
13. Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects.
Hernández-Mijares A; Ascaso JF; Blasco M; Brea Á; Díaz Á; Mantilla T; Pedro-Botet J; Pintó X; Millán J;
Clin Investig Arterioscler; 2019; 31(2):75-88. PubMed ID: 30262442
[TBL] [Abstract][Full Text] [Related]
14. [The combinations of statins and fibrates: pharmacokinetic and clinical implications].
González Santos P
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():7-11. PubMed ID: 25043540
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic targets in the treatment of dyslipidemia: HDL and non-HDL cholesterol].
Brea Hernando ÁJ
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():3-6. PubMed ID: 25043539
[TBL] [Abstract][Full Text] [Related]
16. Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing.
Farnier M
Vasc Health Risk Manag; 2008; 4(5):991-1000. PubMed ID: 19183747
[TBL] [Abstract][Full Text] [Related]
17. [Part II. Combination statin plus fibrate regimens (free and fixed)].
Clin Investig Arterioscler; 2016 Jul; 28 Suppl 3():11-9. PubMed ID: 27473466
[No Abstract] [Full Text] [Related]
18. Fibrates in primary prevention of cardiovascular disease. Comments on the results of a systematic review of the Cochrane Collaboration.
Brea A; Millán J; Ascaso JF; Blasco M; Díaz A; Hernández-Mijares A; Mantilla T; Pedro-Botet JC; Pintó X
Clin Investig Arterioscler; 2018; 30(4):188-192. PubMed ID: 29789212
[TBL] [Abstract][Full Text] [Related]
19. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy.
Aguiar C; Alegria E; Bonadonna RC; Catapano AL; Cosentino F; Elisaf M; Farnier M; Ferrières J; Filardi PP; Hancu N; Kayikcioglu M; Mello E Silva A; Millan J; Reiner Ž; Tokgozoglu L; Valensi P; Viigimaa M; Vrablik M; Zambon A; Zamorano JL; Ferrari R
Atheroscler Suppl; 2015 Sep; 19():1-12. PubMed ID: 26315511
[TBL] [Abstract][Full Text] [Related]
20. The role of fenofibrate in clinical practice.
Zambon A; Cusi K
Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]